InsulinApr 30, 2026
Insulin's side effect profile is narrower than many people assume. Large, long-term trials point to just three main concerns: low blood sugar, modest weight gain, and local skin reactions at injection sites. Fears about insulin causing cancer or heart disease? Not supported by high-quality trial data.
But "narrow" doesn't mean "trivial." Hypoglycemia hits roughly 20% of basal insulin users each year and is a frequent driver of hospitalizations among older adults. Knowing which side effects actually warrant your attention, and which ones you can largely stop worrying about, changes how you approach insulin therapy day to day.
Weight ManagementApr 30, 2026
Spironolactone does not cause clinically meaningful weight gain. Across every population studied, from heart failure patients to women with PCOS to obese postmenopausal women, the pattern is consistent: weight either stays the same or drops slightly. In one large cardiovascular trial with over 1,700 patients, spironolactone actually cut the odds of gaining significant weight nearly in half during the first year.
That's a notably clean signal for a medication many people worry about. If you've been prescribed spironolactone and Googled the side effects list, you may have seen "weight gain" mentioned. The clinical evidence tells a different story.
CortisolApr 30, 2026
The supplements that lower cortisol in clinical trials are largely different from the ones that reduce visceral (belly) fat. That distinction matters, because the two goals require separate strategies. Ashwagandha has the most consistent evidence for lowering cortisol, while specific probiotic strains and certain plant polyphenols show the most promise for visceral fat reduction.
But "promise" deserves a reality check. Effects across the board are moderate, require at least 8 to 16 weeks, and none of these supplements replace calorie control, exercise, and sleep for fat loss and health.
Digestive DisordersApr 30, 2026
Psyllium, the single ingredient in Metamucil, has clinical trial evidence behind four distinct health outcomes: relieving constipation, lowering LDL cholesterol, improving blood sugar control in type 2 diabetes, and supporting modest weight loss. That makes it one of the best-studied fiber supplements you can buy.
The catch is that these results consistently require around 10 grams per day or more, taken for at least several weeks. A single spoonful on a random Tuesday morning probably isn't doing much.
GLP-1Apr 30, 2026
Retatrutide is a triple-receptor agonist (GLP-1, GIP, and glucagon) being developed by Eli Lilly for obesity and type 2 diabetes. It is not yet FDA-approved, but phase 2 trial data give a detailed picture of its side effect profile. If you are exploring GLP-1 medications that are available today, Zepbound (tirzepatide) is the closest approved option.
GLP-1Apr 30, 2026
Tirzepatide has generated enormous interest as a weight loss medication, and Eli Lilly has confirmed work on an oral tablet formulation. But here's what you should know: every clinical trial result published so far comes from the injectable version. No oral tirzepatide tablet has been tested in humans in any published study. This article covers what the injectable data actually shows, because that's the evidence any future oral version will be measured against. If you're considering tirzepatide for weight management, Zepbound is the FDA-approved injectable option available today.
GLP-1Apr 30, 2026
In a head-to-head trial of 338 adults with obesity, weekly semaglutide reduced body weight by about 16% while daily liraglutide reached just 6% over the same 68 weeks. That gap matters. The choice of GLP-1 drug, the dose, and how long you stay on it collectively determine whether you lose a modest amount of weight or a quarter of your starting body mass.
GLP-1 receptor agonists have become the most effective non-surgical weight loss treatments ever tested in large trials. But the category includes several different drugs with meaningfully different results, and the details determine what you can realistically expect.
GLP-1Apr 29, 2026
Retatrutide and tirzepatide both belong to the new generation of incretin-based weight loss drugs, but they work through different receptor combinations. Tirzepatide (sold as Zepbound for weight management and Mounjaro for type 2 diabetes) is FDA-approved and available now. Retatrutide is still in phase 3 clinical trials and is not yet approved for any use. Here is what the published research shows about how they compare.
NutritionApr 29, 2026
Protein bars can be a healthy, convenient protein source, but many commercial options are loaded with added sugars, unhealthy fats, and additives that undermine their supposed health benefits. A study of foods with protein claims in Spain found that products carrying protein labels were actually 13% more likely to be classified as "less healthy" by objective nutrient profiling standards than products without such claims.
The word "protein" on the package doesn't guarantee you're making a good choice. This article will walk you through exactly what to look for when you flip that bar over, with specific numbers and red flags backed by clinical research.
PCOSApr 28, 2026
If you have PCOS and feel like fat gravitates to your midsection no matter what you do, you're not imagining it. Research consistently shows that women with PCOS accumulate more abdominal fat than women without it, even when they weigh the same overall. This pattern has a name in online communities ("PCOS belly"), and while that's not a medical diagnosis, the science behind it is real and worth understanding.
PCOS belly isn't just a cosmetic concern. It's driven by a specific hormonal and metabolic loop involving insulin resistance and excess androgens, and it independently raises your risk for type 2 diabetes, metabolic syndrome, and cardiovascular disease. The good news is that targeted lifestyle changes (and, when needed, certain medications) can break that cycle.
MedicationsApr 28, 2026
Fluoxetine, sold as Prozac, is one of the most widely prescribed antidepressants on the planet, and one of the most common fears people have about starting it is gaining weight. But when you look at the actual human trial data, the picture flips. Meta-analyses of randomized trials in overweight and obese adults show fluoxetine produces modest weight loss of roughly 1 to 3 kg compared to placebo, particularly at doses of 60 mg/day or higher over 12 weeks or less. A large systematic review of psychotropic medications found fluoxetine associated with an average 1.3 kg loss.
That's not a typo. The drug most people worry will make them heavier is, if anything, slightly more likely to make them lighter.
DiabetesApr 28, 2026
Jardiance (empagliflozin) reliably shaves off about 2 to 3 kilograms in people with type 2 diabetes, roughly 3 to 4% of body weight over three to six months. That's consistent and measurable, but it puts Jardiance firmly in the "mild" weight loss category, well below the 10%-plus losses seen with GLP-1 medications like semaglutide. If you're taking Jardiance and noticing the scale drift downward, that's expected. If you're considering it primarily for weight loss, the research suggests you'd be disappointed.
Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor, a class of drug designed to manage type 2 diabetes, heart failure, and kidney disease. Weight loss is a real but secondary effect, more of a metabolic bonus than the main event.
DiabetesApr 28, 2026
Bydureon (exenatide extended-release) can drop HbA1c by roughly 1.3 to 1.6 percentage points with a single weekly injection. That's a meaningful reduction for adults with type 2 diabetes who aren't getting enough from diet, exercise, and oral medications. But here's the tension worth understanding: head-to-head data show it's slightly less potent on both blood sugar and weight than liraglutide or semaglutide, two GLP-1 receptor agonists that now dominate the conversation.
So where does that leave Bydureon? Still effective, still convenient, but no longer the frontrunner. Whether it makes sense for you depends on what you're prioritizing and what trade-offs you're willing to accept.
Cardiovascular HealthApr 28, 2026
People taking semaglutide 2.4 mg lost an average of 14.9% of their body weight over 68 weeks, and half of them lost more than 15%. That kind of result used to require surgery. Now it comes in a weekly injection, and a pill version is catching up. GLP-1 medications have become the most talked-about drug class in a generation, but the clinical data behind them goes far deeper than weight loss alone.
These drugs were originally developed for type 2 diabetes. Along the way, researchers discovered they also reduce heart attacks, strokes, and even <>. A meta-analysis pooling data from over 60,000 patients found that GLP-1 medications cut major cardiovascular events by 14% and all-cause mortality by 12%. That's a rare combination: a drug class that helps people lose weight and live longer.
CancerApr 28, 2026
Megestrol acetate can make you hungrier and help you gain a little weight. But across large systematic reviews, it has never been shown to help people live longer. That tension sits at the heart of every decision to prescribe this drug: it treats a symptom (wasting, lost appetite) while carrying real risks to your endocrine system, your blood vessels, and your metabolism. Whether that tradeoff makes sense depends entirely on what problem you're trying to solve.
Megestrol acetate is a synthetic progestin, meaning it mimics progesterone. It was originally developed as a hormonal cancer treatment and is still used that way. But its most common role today is as an appetite stimulant for people dealing with the severe weight loss and appetite collapse that come with cancer, AIDS, and other serious illnesses.
Cholesterol ManagementApr 28, 2026
Across multiple human studies, including randomized trials, long-term treatment data, and post-surgical follow-ups, atorvastatin does not appear to cause weight gain. That is not a hedged, "maybe-maybe-not" conclusion. It is a consistent finding that shows up in different patient populations, at different doses, and over different timeframes. If the number on your scale is climbing while you take atorvastatin, the research strongly suggests something else is responsible.
This matters because statins are among the most widely prescribed drugs in the world, and weight concerns are one of the reasons people consider stopping them. The evidence available gives a clear picture worth understanding.
Weight LossApr 28, 2026
Clinical evidence shows higher doses produce more weight loss, and the standard target of 2.4 mg per week exists for good reason. But the smartest strategy isn't simply "get to the top dose as fast as possible." It's a personalized approach that balances effectiveness, side effects, cost, and your long-term ability to stick with treatment. This article breaks down what the trials and real-world data actually show, so you can have a more informed conversation with your doctor.
SupplementationApr 28, 2026
Isolated soluble fibers, the same types used in most fiber gummies (inulin, fructooligosaccharides, resistant starch), produce small but measurable improvements in body weight, blood sugar, and body composition. In adults with overweight or obesity, these fiber supplements reduced body weight by roughly 2.5 kg, along with improvements in BMI, body fat, fasting glucose, and insulin, over study periods ranging from 2 to 17 weeks.
That's a genuine effect, not a marketing fantasy. But it's also not the whole story. Most of the big, impressive health associations tied to fiber come from diets rich in whole plant foods, which bundle fiber with micronutrients and phytochemicals that an isolated supplement simply doesn't contain. Fiber gummies occupy a real but narrow lane.
ProbioticsApr 28, 2026
A single randomized controlled trial gave pasteurized Akkermansia muciniphila to overweight, insulin-resistant adults for three months. The results were genuinely impressive: insulin sensitivity improved roughly 29%, fasting insulin dropped, total cholesterol fell, and participants lost modest amounts of weight and fat mass. Short-term safety looked good. That's the best news this bacterium has going for it right now, and it's worth taking seriously.
It's also worth taking carefully. That one trial is, so far, the only controlled human experiment with direct Akkermansia supplementation. The rest of the evidence comes from animal research and observational data, and some of it raises real concerns about who might be helped and who might be harmed.
MedicationsApr 28, 2026
The average weight gain on Lexapro (escitalopram) is genuinely tiny. One 26-week trial put it at roughly 0.14 kg. But that number is nearly useless for predicting your experience, because roughly 10 to 20% of users gain 5% or more of their body weight over months to years. If you weigh 150 pounds, that's at least 7.5 pounds. Enough to notice. Enough to matter.
Whether Lexapro affects your weight depends less on the drug's average profile and more on your individual risk factors, how long you take it, and what alternatives exist. The research paints a surprisingly clear picture of who's most vulnerable.
